Oruka Therapeutics Reports Third Quarter 2026 GAAP EPS in Line with Expectations
Oruka Therapeutics (NASDAQ: ORKA) reported its third-quarter 2026 financial results, announcing a GAAP earnings per share (EPS) of -$0.63, which aligned with market expectations. The company's net cash used in operating activities for the quarter was $44.3 million, an increase from $21.6 million in the prior period. Despite the quarterly loss, Oruka maintains a strong liquidity position. As of September 30, 2026, the company reported having $1.2 billion in cash, cash equivalents, and marketable securities to fund its ongoing operations and development programs.
Tickers: $ORKA
Topics: cash_flow earnings financial_results
Read the full article at Seeking Alpha
Part of the story St. Joe Reports Q3 GAAP EPS of $0.65 and Revenue of $156.2 Million (30 articles)